Skip to main content
. 2020 Jun 19;10(6):70. doi: 10.1038/s41408-020-0336-z

Table 1.

Patient Characteristics of the pPCL cohort compared to a previously published MM cohort17,18.

Patient clinical characteristics pPCL (n = 23) MM (n = 1273) p value
Median age at diagnosis (Min−Max) 59 (36–77) 66 (27–93)
Age ≥ 65 years (%) 9/23 (39%) 693/1273 (54%) NS
Isotype (Kappa/Lambda) 11/12
ISS stage I (%) 0/23 (0%) 360/1170 (31%) <0.01
ISS stage II (%) 1/23 (4%) 442/1170 (38%) <0.01
ISS stage III (%) 22/23 (96%) 368/1170 (31%) <0.0001
Elevated LDH (%) 13/17 (76%)
Elevated creatinine (≥2 mg/dL) 18/22 (81%)
t(11;14) 5/23 (22%) 234/1273 (18%) NS
t(14;16) or t(14;20) 10/23 (43%) 62/1273 (5%) <0.0001
t(4;14) 2/23 (9%) 58/461 (13%) NS
Hyperdiploidy 3/23 (13%) 456/1074 (42%) <0.01
Gain of chromosome 1q 17/23 (74%) 314/1074 (29%) <0.0001
 1q duplication (=3 copies) 13/23 (57%)
 1q amplification (≥4 copies) 4/23 (17%)
C-Myc translocations
 Ig partner loci (IGH, IGK, IGL) 5/23 (22%) 202/751 (27%) NS
 Non-Ig partner loci (FAM46C, MYNN, SPARC, QRSL1, PLXNA4, CDH7, RNF123) 9/23 (39%)